This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshida, T Articles by Mitsuhashi, S Search for Related Content PubMed PubMed Citation Articles by Yoshida, T Articles by Mitsuhashi, S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 April; 37(4): 793-800

Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.

T Yoshida and S Mitsuhashi

Episome Institute, Gunma, Japan.

ABSTRACT

The in vitro antibacterial activity of NM394 was compared with those of other new quinolones. NM394 showed potent and broad-spectrum antibacterial activity against 2,606 recent clinical isolates. The activity of NM394 against gram-positive bacteria was 2- to 16-fold less than that of tosulfoxacin and sparfloxacin but was comparable to that of ofloxacin. Only against Streptococcus pyogenes was the activity of NM394 equal to that of sparfloxacin. Against gram-negative bacteria, NM394 showed antibacterial activity equal to that of ciprofloxacin. Against quinolone-resistant Pseudomonas aeruginosa (norfloxacin MIC, > 6.25 micrograms/ml), the activity of NM394 was greater than those of the other agents tested. NM394 was rapidly bactericidal at concentrations near the MIC. NM394 inhibited supercoiling activities of DNA gyrase purified from Staphylococcus aureus, Escherichia coli, and P. aeruginosa; the 50% inhibitory concentrations were 18.0, 0.41, and 2.05 micrograms/ml, respectively.

---

Antimicrob Agents Chemother. 1993 April; 37(4): 793-800

This article has been cited by other articles:

• Montanari, M. P., Mingoia, M., Varaldo, P. E. (2001). In Vitro Antibacterial Activities of AF 3013, the Active Metabolite of Prulifloxacin, against Nosocomial and Community Italian Isolates. Antimicrob. Agents Chemother. 45: 3616-3622 [Abstract] [Full Text]  
• Tullio, V., Cuffini, A. M., Bonino, A., Palarchio, A. I., Roana, J., Mandras, N., Rossi, V., Carlone, N. A. (2000). Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin. J Antimicrob Chemother 46: 241-247 [Abstract] [Full Text]